Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 This is to certify that the details of securities dematerialized and rematerialized during the quarter and year ended March 31, 2022, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 have been furnished to all the Stock Exchanges where the shares of Biocon Limited are listed. The certificate from our RTA i.e. M/s. KFin Technologies Limited (Formerly known as M/s. KFin Technologies Private Limited) dated April 6, 2022 confirming the above, is enclosed for your reference.
14-04-2022
Bigul

BIOCON LTD. - 532523 - Board to consider FY22 Results & Dividend on April 28, 2022

 Biocon Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on April 28, 2022, inter alia, to approve and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading (''the Code'') of the Company, has been closed from April 01, 2022 to April 30, 2022 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations.
04-04-2022
Bigul

BIOCON LTD. - 532523 - Board Meeting Intimation for Intimation For The Board Meeting And Trading Window Closure

 BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2022 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, April 28, 2022, inter alia, to approve and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from April 1, 2022 to April 30, 2022 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations.
04-04-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
01-04-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Biocon Biologics' Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion
01-04-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
31-03-2022

Glasgow Uni names research centre after John Shaw and Kiran Mazumdar-Shaw

 The 116 million building will officially open in June 2022 and will have over 500 researchers from a range of disciplines, facilitating collaborative research, Biocon said in a statement.
29-03-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw.
29-03-2022
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
24-03-2022

Kiran Mazumdar-Shaw elected as fellow of Royal Society of Edinburgh

 Mazumdar-Shaw, who is also the Executive Chairperson of Biocon Biologics, will be joining RSE's current fellowship of around 1,700 fellows.
23-03-2022
Next Page
Close

Let's Open Free Demat Account